AUA Advanced Prostate Cancer Guidelines Webcast (2024)

This course will be comprehensive AUA Guidelines on advanced prostate cancer in the management and outcomes of men with advanced, metastatic and castrate-resistant prostate cancer (CRPC). The course will include risk stratification, germline testing, PET imaging, the use of androgen deprivation therapy in combination with novel androgen axis therapy and chemotherapy in men with newly diagnosed metastatic hormone-sensitive prostate cancer. Early treatment intensification and evidenced-based guidelines will be covered. The course will also cover nonmetastatic CRPC and treatment for metastatic CRPC. The use of sequencing, combination therapy, somatic testing and precision medicine with PARP inhibitors will also be discussed. The course will also cover emerging salvage therapies for CRPC.


This educational activity is supported by independent educational grants from:

Astellas, Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC, Lantheus Medical Imaging, Merck & Co., Inc., Novartis Pharmaceuticals Corporation, Pfizer, Inc.

Learning Objectives

At the conclusion of this activity, participants will be able to:

  1. Identify appropriate use of genetic testing and genetic counseling.
  2. Identify appropriate use of somatic testing and treatments related to specific genetic alterations.
  3. Identify appropriate combination therapy with androgen deprivation therapy plus novel androgen access therapies and chemotherapy. Early treatment intensification will be discussed in metastatic hormone-sensitive prostate cancer.
  4. Identify the treatments for nonmetastatic CRPC and oncologic outcomes based on AUA/SUO (Society of Urologic Oncology) Guidelines.
  5. Cancel patients on available treatment options for CRPC as well as combination therapy and sequencing based on AUA/SUO Guidelines.
Course summary
Available credit: 
  • 2.00 AMA PRA Category 1 Credit™
  • 2.00 Non-Physician Participation
Course opens: 
Course expires: 


NameCompany NameRelationship TypeEnd Date
Cookson, Michael S.PfizerConsultant or AdvisorCurrent
ProkariumConsultant or Advisor10/26/2022
Nonagen Bioscience Corp.Consultant or Advisor07/11/2023
Janssen PharmaceuticalsConsultant or Advisor11/30/2022
LantheusConsultant or Advisor09/24/2022
Cookson, Michael S.Progenics Phamaceuticals, Inc. (Lanthues)Consultant or AdvisorCurrent
Jarrard, David F.No relevant financial relationships to disclose
Kibel, Adam S.ProfoundConsultant or Advisor01/01/2024
JanssenConsultant or AdvisorCurrent
Bristol-Myers SquibbConsultant or AdvisorCurrent
MerckConsultant or Advisor10/24/2022
advantageneConsultant or Advisor12/01/2022
ExlexisConsultant or Advisor07/08/2022
MyovantConsultant or Advisor05/06/2022
Blue EarthConsultant or Advisor10/24/2022
RocheConsultant or Advisor10/24/2022
CellvaxConsultant or AdvisorCurrent
CandelConsultant or AdvisorCurrent
PfizerConsultant or Advisor05/02/2023
Lowrance, William ThomasVesica HealthConsultant or AdvisorCurrent



PDF iconEducation Council Disclosures


PDF iconCOI Review Work Group Disclosures

AUA Office of Education Staff has nothing to disclose.

All relevant financial relationships have been mitigated.

Method of Participation: Learners will participate in this online educational activity by viewing the webcast and completing the post-test and evaluation. To claim CME credit for this enduring material, learners must complete the post-test, passing with 80% accuracy, and submit the program evaluation.

Release Date: May, 2024
Expiration Date: May, 2025

Accreditation: The American Urological Association (AUA) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation: The American Urological Association designates this enduring material for a maximum of 2 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. 

Other Learners: The AUA is not accredited to offer credit to participants who are not MDs or DOs. However, the AUA will issue documentation of participation that states that the activity was certified for AMA PRA Category 1 Credit™.

Evidence Based Content: It is the policy of the AUA to ensure that the content contained in this CME activity is valid, fair, balanced, scientifically rigorous, and free of commercial bias.

AUA Disclosure Policy: All persons in a position to control the content of an educational activity (i.e., activity planners, presenters, authors) are required to disclose to the provider all financial relationships with any commercial interest (aka ineligible company) during the previous 24 months. The AUA must determine if the individual’s relationships may influence the educational content and mitigate any conflicts of interest prior to the commencement of the educational activity. The intent of this disclosure is not to prevent individuals with relevant financial relationships from participating, but rather to provide learners information with which they can make their own judgments.

Mitigation of Identified Conflict of Interest: All disclosures will be reviewed by the AUA Conflict of Interest (COI) Review Work Group Chair and/or Vice Chair for identification of conflicts of interest. The AUA COI Review Work Group, working with Office of Education staff, will document the mechanism(s) for management and mitigation of the conflict of interest and final approval of the activity will be documented prior to implementation. 

Off-label or Unapproved Use of Drugs or Devices: The audience is advised that this continuing medical education activity may contain reference(s) to off-label or unapproved uses of drugs or devices. Please consult the prescribing information for full disclosure of approved uses.


Disclaimer: The opinions and recommendations expressed by faculty, authors and other experts whose input is included in this program are their own and do not necessarily represent the viewpoint of the AUA.

Reproduction Permission: Reproduction of written materials developed for this AUA course is prohibited without the written permission from individual authors and the American Urological Association.

Available Credit

  • 2.00 AMA PRA Category 1 Credit™
  • 2.00 Non-Physician Participation
Please login or register to take this course.